Plain-English translation of NCT06170788 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether combined with works better than alone for treating advanced non-small cell lung cancer. is an immunotherapy drug already used to treat this cancer, and researchers want to see if adding the new medication improves survival. About 614 patients will participate.
is a helpful treatment for advanced lung cancer, but many patients still experience disease progression. This trial exists to see if combining it with a new drug can help more patients live longer and control their cancer better.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the combination of the new medication plus , or alone. You will receive intravenous infusions every 6 weeks for approximately 18 cycles (about 9 months total). The combination group will receive additional infusions of the new drug on specific days within each cycle, along with supportive medications to help manage side effects. You will have regular visits for monitoring, blood tests, and imaging scans to track how your cancer responds to treatment.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
United States